<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?DTDIdentifier.IdentifierValue http://null/schema/dtds/document/fulltext/xcr/xocs-article.xsd?><?DTDIdentifier.IdentifierType schema?><?SourceDTD.DTDName xocs-article.xsd?><?SourceDTD.Version 1.0?><?ConverterInfo.XSLTName ftrr2jats.xsl?><?ConverterInfo.Version 1?><?origin publisher?><front><journal-meta><journal-id journal-id-type="nlm-ta">J King Saud Univ Sci</journal-id><journal-id journal-id-type="iso-abbrev">J King Saud Univ Sci</journal-id><journal-title-group><journal-title>Journal of King Saud University. Science</journal-title></journal-title-group><issn pub-type="ppub">1018-3647</issn><issn pub-type="epub">2213-686X</issn><publisher><publisher-name>The Author(s). Published by Elsevier B.V. on behalf of King Saud University.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7366079</article-id><article-id pub-id-type="publisher-id">S1018-3647(20)30217-2</article-id><article-id pub-id-type="doi">10.1016/j.jksus.2020.07.007</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Structure-based virtual screening of phytochemicals and repurposing of FDA approved antiviral drugs unravels lead molecules as potential inhibitors of coronavirus 3C-like protease enzyme</article-title></title-group><contrib-group><contrib contrib-type="author" id="au005"><name><surname>Bahadur Gurung</surname><given-names>Arun</given-names></name><email>arunbgurung@gmail.com</email><xref rid="af005" ref-type="aff">a</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au010"><name><surname>Ajmal Ali</surname><given-names>Mohammad</given-names></name><xref rid="af010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="au015"><name><surname>Lee</surname><given-names>Joongku</given-names></name><email>joongku@cnu.ac.kr</email><xref rid="af015" ref-type="aff">c</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author" id="au020"><name><surname>Abul Farah</surname><given-names>Mohammad</given-names></name><xref rid="af020" ref-type="aff">d</xref></contrib><contrib contrib-type="author" id="au025"><name><surname>Mashay Al-Anazi</surname><given-names>Khalid</given-names></name><xref rid="af020" ref-type="aff">d</xref></contrib><aff id="af005"><label>a</label>Department of Basic Sciences and Social Sciences, North-Eastern Hill University, Shillong 793022, Meghalaya, India</aff><aff id="af010"><label>b</label>Department of Botany and Microbiology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia</aff><aff id="af015"><label>c</label>Department of Environment and Forest Resources, Chungnam National University, 99 Daehak-ro, Yuseong-gu, Daejeon 34134, Republic of Korea</aff><aff id="af020"><label>d</label>Genetics Laboratory, Department of Zoology, College of Science, King Saud University, Riyadh 11451, Saudi Arabia</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding authors. <email>arunbgurung@gmail.com</email><email>joongku@cnu.ac.kr</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>17</day><month>7</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="ppub"><month>9</month><year>2020</year></pub-date><pub-date pub-type="epub"><day>17</day><month>7</month><year>2020</year></pub-date><volume>32</volume><issue>6</issue><fpage>2845</fpage><lpage>2853</lpage><history><date date-type="received"><day>13</day><month>5</month><year>2020</year></date><date date-type="rev-recd"><day>9</day><month>6</month><year>2020</year></date><date date-type="accepted"><day>12</day><month>7</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; 2020 The Author(s)</copyright-statement><copyright-year>2020</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="ab005"><p>Coronaviruses are enveloped positive-strand RNA viruses belonging to family <italic>Coronaviridae</italic> and order <italic>Nidovirales</italic> which cause infections in birds and mammals. Among the human coronaviruses, highly pathogenic ones are Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) which have been implicated in severe respiratory syndrome in humans. There are no approved antiviral drugs or vaccines for the treatment of human CoV infection to date. The recent outbreak of new coronavirus pandemic, coronavirus disease 2019 (COVID-19) has caused a high mortality rate and infections around the world which necessitates the need for the discovery of novel anti-coronaviral drugs. Among the coronaviruses proteins, 3C-like protease (3CL<sup>pro</sup>) is an important drug target against coronaviral infection as the auto-cleavage process catalysed by the enzyme is crucial for viral maturation and replication. The present work is aimed at the identification of suitable lead molecules for the inhibition of 3CL<sup>pro</sup> enzyme via a computational screening of the Food and Drug Administration (FDA) approved antiviral drugs and phytochemicals. Based on binding energies and molecular interaction studies, we shortlisted five lead molecules (both FDA approved drugs and phytochemicals) for each enzyme targets (SARS-CoV-2 3CL<sup>pro</sup>, SARS-CoV 3CL<sup>pro</sup> and MERS-CoV 3CL<sup>pro</sup>). The lead molecules showed higher binding affinity compared to the standard inhibitors and exhibited favourable hydrophobic interactions and a good number of hydrogen bonds with their respective targets. A few promising leads with dual inhibition potential were identified among FDA approved antiviral drugs which include DB13879 (Glecaprevir), DB09102 (Daclatasvir), molecule DB09297 (Paritaprevir) and DB01072 (Atazanavir). Among the phytochemicals, 11,646,359 (Vincapusine), 120,716 (Alloyohimbine) and 10,308,017 (Gummadiol) showed triple inhibition potential against all the three targets and 102,004,710 (18-Hydroxy-3-epi-alpha-yohimbine) exhibited dual inhibition potential. Hence, the proposed lead molecules from our findings can be further investigated through <italic>in vitro</italic> and <italic>in vivo</italic> studies to develop into potential drug candidates against human coronaviral infections.</p></abstract><kwd-group id="kg005"><title>Keywords</title><kwd>Coronaviruses</kwd><kwd>3C-like protease</kwd><kwd>SARS-CoV</kwd><kwd>MERS-CoV</kwd><kwd>Molecular docking</kwd><kwd>Virtual screening</kwd><kwd>FDA approved drugs</kwd><kwd>Antiviral drugs</kwd><kwd>Phytochemicals</kwd></kwd-group></article-meta></front><body><sec id="s0005"><label>1</label><title>Introduction</title><p id="p0005">Coronaviruses belong to the <italic>Coronavirinae</italic> subfamily, family <italic>Coronaviridae</italic> and order <italic>Nidovirales</italic>. The subfamily members based on genomic structure and phylogenetic study can be classified under four genera &#x02014; <italic>Alpha-, Beta-, Gamma- and Delta-coronavirus</italic> (<xref rid="b0030" ref-type="bibr">Cui et al., 2019</xref>). The first two genera cause infections in only mammals while birds and mammals are commonly infected by <italic>Gamma- and Delta-coronaviruses</italic> (<xref rid="b0180" ref-type="bibr">Woo et al., 2012</xref>). While <italic>Alpha-coronaviruses</italic> and <italic>Beta-coronaviruses</italic> are known to cause gastroenteritis in animals, in humans, they commonly cause respiratory distress (<xref rid="b0030" ref-type="bibr">Cui et al., 2019</xref>). There are four human coronaviruses such as HCoV-229E, HKU1, HCoV-NL63 and HCoV-OC43 which induce mild upper respiratory infections and two highly pathogenic ones, such as Severe Acute Respiratory Syndrome coronavirus (SARS-CoV) and Middle East Respiratory Syndrome coronavirus (MERS-CoV) implicated in severe respiratory syndrome in humans (<xref rid="b0050" ref-type="bibr">Forni et al., 2017</xref>, <xref rid="b0155" ref-type="bibr">Su et al., 2016</xref>). All human coronaviruses are reported to have animal origins based on the current sequence studies, for example, SARS-CoV, MERS-CoV, HCoV-229E and HCoV-NL63 have been originated in bats while HKU1 and HCoV-OC43 are probably linked to rodents (<xref rid="b0050" ref-type="bibr">Forni et al., 2017</xref>, <xref rid="b0155" ref-type="bibr">Su et al., 2016</xref>). The intermediate hosts such as domestic animals may play a significant role in facilitating the easy transfer of viruses from natural hosts to humans (<xref rid="b0030" ref-type="bibr">Cui et al., 2019</xref>). Furthermore, domestic animals themselves are susceptible to bat-borne or closely related coronavirus diseases (<xref rid="b0085" ref-type="bibr">Lacroix et al., 2017</xref>, <xref rid="b0150" ref-type="bibr">Simas et al., 2015</xref>). At present, 7 of 11 species of <italic>Alpha-coronavirus</italic> specified by the International Committee on Taxonomy of Viruses (ICTV) and 4 of 9 species of <italic>Beta-coronavirus</italic> have been reported only in bats. Consequently, bats are probably the main natural reservoirs of <italic>Alpha- and Beta-coronaviruses</italic> (<xref rid="b0180" ref-type="bibr">Woo et al., 2012</xref>).</p><p id="p0010">Coronaviruses are enveloped viruses of about 80&#x02013;120&#x000a0;nm in diameter, with round and often pleiomorphic virions. They contain positive-strand RNA, with the largest genome (~30&#x000a0;kb) known till date (<xref rid="b0090" ref-type="bibr">Lai, 2001</xref>). A helical capsid found within the viral membrane is composed of genomic RNA complexed with the basic nucleocapsid (N) protein. All coronaviruses display at least three membrane viral proteins. This includes type I glycoprotein, spike (S) protein which forms peplomers on the surface and gives a characteristic crown-like appearance, the membrane (M) protein and a small membrane protein, an envelope protein (E). All coronaviruses have a similar genomic structure (<xref rid="b0170" ref-type="bibr">Weiss and Navas-Martin, 2005</xref>). The replicase gene located within 5&#x02032; region approximately 20&#x02013;22&#x000a0;kb encodes several enzymatic activities. The gene products of the replicase are encoded within two very large open reading frames, ORFs 1a and 1b, which are translated by a frameshift mechanism into two large polypeptides, pp1a and pp1ab (<xref rid="b0055" ref-type="bibr">Gorbalenya, 2001</xref>, <xref rid="b0100" ref-type="bibr">Lee et al., 1991</xref>). With the help of S protein, coronaviruses bind to their specific host cellular receptors. On gaining entry into the cell, pp1a and pp1ab are translated from the viral genome RNA, ORFs 1a and 1b (<xref rid="b0020" ref-type="bibr">Bredenbeek et al., 1990</xref>, <xref rid="b0025" ref-type="bibr">Brian and Baric, 2005</xref>). The ORF1a encodes a picornavirus 3C-like protease (3CL<sup>pro</sup>) and one or two papain-like proteases (PL<sup>pro</sup> or PLP). These proteases catalyze the processing of viral pp1a and pp1ab into the mature replicase proteins (<xref rid="b0100" ref-type="bibr">Lee et al., 1991</xref>, <xref rid="b0200" ref-type="bibr">Ziebuhr et al., 2001</xref>). The enzymes such as RNA-dependent RNA polymerase (RdRp), a helicase (1&#x000a0;1&#x000a0;6) and others are encoded in ORF 1b and processed from pp1ab (<xref rid="b0055" ref-type="bibr">Gorbalenya, 2001</xref>). The metabolism of coronavirus RNA and disruption of host cell processes are believed as a result of the catalytic activities of various enzymes (<xref rid="b0195" ref-type="bibr">Ziebuhr, 2005</xref>).</p><p id="p0015">As aforementioned, SARS- and MERS-CoVs genome harbours two ORFs: ORF1a and ORF1b wherein ORF1a encodes two cysteine proteases viz; a papain-like protease (PL<sup>pro</sup>) and a 3C-like protease (3CL<sup>pro</sup>) also known as main protease (M<sup>pro</sup>). While PL<sup>pro</sup> manages cleavage on the first three cutting sites of its polyprotein, 3CL<sup>pro</sup> is responsible for cleavage at other eleven positions causing the release of sixteen non-structural proteins (nsp) (<xref rid="b0075" ref-type="bibr">Jo et al., 2020</xref>). The crystal structures of SARS- and MERS-CoVs 3CL<sup>pro</sup> reveal the presence of three structural domains in each monomer wherein domains I and II has a characteristic chymotrypsin-like fold with a catalytic cysteine and are linked to a third C-terminal domain by a long loop (<xref rid="b0125" ref-type="bibr">Needle et al., 2015</xref>). Therefore, 3CL<sup>pro</sup> is an important drug target against coronaviral infection as the auto-cleavage process is indispensable for viral maturation and replication (<xref rid="b0075" ref-type="bibr">Jo et al., 2020</xref>).</p><p id="p0020">The recent outbreak of new coronavirus pandemic or coronavirus disease 2019 (COVID-19) has caused high mortality rate and infections around the world (<xref rid="b0185" ref-type="bibr">Wu et al., 2020</xref>, <xref rid="b0190" ref-type="bibr">Zhou et al., 2020</xref>) warrants the need for the discovery of new effective antiviral therapeutics against coronaviral infections. There are no approved antiviral drugs or vaccines for the treatment of human CoV infection to date, though many candidate therapeutics have been investigated in pre-clinical studies (<xref rid="b0005" ref-type="bibr">Abd El-Aziz and Stockand, 2020</xref>, <xref rid="b0035" ref-type="bibr">Dhama et al., 2020</xref>, <xref rid="b0060" ref-type="bibr">Graham et al., 2013</xref>, <xref rid="b0110" ref-type="bibr">Lundstrom, 2020</xref>, <xref rid="b0135" ref-type="bibr">Padron-Regalado, 2020</xref>). Although many attempts have been previously made by workers to identify specific inhibitors for 3CL<sup>pro</sup> enzymes, a few studies have been done to target all the three coronavirus protease enzymes (SARS-CoV-2 3CL<sup>pro</sup>, SARS-CoV 3CL<sup>pro</sup> and MERS-CoV 3CL<sup>pro</sup>) using small molecules. In this study we aimed at finding suitable lead molecules for the inhibition of 3CL<sup>pro</sup> enzymes through virtual screening of two chemical datasets viz; Food and Drug Administration (FDA) approved antiviral drugs and selected phytochemicals. We have proposed five lead molecules as potential inhibitors for each enzyme targets. These lead molecules could be further investigated for developing as drugs against anti-coronaviral infection.</p></sec><sec id="s0010"><label>2</label><title>Materials and methods</title><sec id="s0015"><label>2.1</label><title>Selection and retrieval of phytochemicals and FDA approved drugs</title><p id="p0025">A total of 263 phytochemicals and 75 FDA approved antiviral drugs were retrieved from the database of Indian Plants, Phytochemistry And Therapeutics (IMPPAT) (<xref rid="b0115" ref-type="bibr">Mohanraj et al., 2018</xref>) and DrugBank database (<xref rid="b0175" ref-type="bibr">Wishart et al., 2008</xref>) respectively. The three-dimensional structure of the molecules was downloaded in SDF format and the molecules whose only two-dimensional structures were available, were converted into the three-dimensional form using OpenBabel software version 2.4.1 (<xref rid="b0130" ref-type="bibr">O&#x02019;Boyle et al., 2011</xref>) and optimized using the Merck molecular force field (MMFF94) (<xref rid="b0065" ref-type="bibr">Halgren, 1996</xref>).</p></sec><sec id="s0020"><label>2.2</label><title>Screening of drug-like compounds:</title><p id="p0030">The drug-like compounds from the phytochemicals set were filtered based on Lipinski&#x02019;s rule of five (<xref rid="b0105" ref-type="bibr">Lipinski, 2004</xref>), Veber&#x02019;s rule (<xref rid="b0165" ref-type="bibr">Veber et al., 2002</xref>) and Adsorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) physicochemical parameters. The physicochemical properties of the compounds were evaluated using DataWarrior program version 5.0 (<xref rid="b0145" ref-type="bibr">Sander et al., 2015</xref>).</p></sec><sec id="s0025"><label>2.3</label><title>Protein-preparation</title><p id="p0035">The high resolution three dimensional X-ray crystal structures of the enzyme target: SARS-CoV-2 3CL<sup>pro</sup>, SARS-CoV 3CL<sup>pro</sup> and MERS-CoV 3CL<sup>pro</sup> were retrieved from protein data bank (PDB) (<ext-link ext-link-type="uri" xlink:href="http://www.rcsb.org/" id="ir005">http://www.rcsb.org/</ext-link>) using their accession IDs 6Y2F, 3TNT and 5WKK at a resolution of 1.95&#x000a0;&#x000c5;, 1.59&#x000a0;&#x000c5; and 1.55&#x000a0;&#x000c5; respectively. The heteroatoms including ions, cocrystal ligands (O6K, G85 and AW4 corresponding to PDB IDs: 6Y2F, 3TNT and 5WKK respectively) and water molecules were removed. Hydrogen atoms and Kolmann charges were added to the protein using AutoDockTools 1.5.6 (<xref rid="b0120" ref-type="bibr">Morris et al., 2009</xref>) and the proteins were converted into PDBQT format.</p></sec><sec id="s0030"><label>2.4</label><title>Ligand preparation</title><p id="p0040">The selected compounds were prepared for docking using AutoDockTools 1.5.6 (<xref rid="b0120" ref-type="bibr">Morris et al., 2009</xref>). Hydrogen atoms and Gasteiger charges were added to the selected compounds and the torsions were defined for each compound. The structures were saved in PDBQT format.</p></sec><sec id="s0035"><label>2.5</label><title>Molecular docking study</title><p id="p0045">The binding affinity of each selected compound along with the control with the three enzyme targets was determined using molecular docking approach. The binding sites for the docking were defined by placing a grid box of suitable dimensions centred at each cocrystallized ligand (<xref rid="t0005" ref-type="table">Table 1</xref>
). Autodock Vina was used for carrying out molecular docking, which performs docking calculations based on sophisticated gradient optimization method (<xref rid="b0160" ref-type="bibr">Trott and Olson, 2010</xref>). The binding poses were clustered and ranked in the order of their binding affinities. The molecular interactions (hydrogen bonds and hydrophobic interactions between the target proteins and compounds were studied using LigPlot&#x000a0;+&#x000a0;version 1.4.5 (<xref rid="b0095" ref-type="bibr">Laskowski and Swindells, 2011</xref>).<table-wrap position="float" id="t0005"><label>Table 1</label><caption><p>The grid box parameters considered for molecular docking studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Enzyme targets</th><th colspan="3">AutoDock Vina Search Space<hr/></th></tr><tr><th>Center</th><th>Dimensions (&#x000c5;)</th><th>Exhaustiveness</th></tr></thead><tbody><tr><td>SARS-CoV-2 3CL<sup>pro</sup></td><td>x: 10.9372, y: &#x02212;2.0146, z: 18.2692</td><td>25&#x000a0;&#x000d7;&#x000a0;25&#x000a0;&#x000d7;&#x000a0;25</td><td>8</td></tr><tr><td>SARS-CoV 3CL<sup>pro</sup></td><td>x: 25.1486, y: 44.1145, z: &#x02212;5.6121</td><td>25&#x000a0;&#x000d7;&#x000a0;25&#x000a0;&#x000d7;&#x000a0;25</td><td>8</td></tr><tr><td>MERS-CoV 3CL<sup>pro</sup></td><td>x: &#x02212;21.9860, y: 25.6036, z: 4.0045</td><td>25&#x000a0;&#x000d7;&#x000a0;25&#x000a0;&#x000d7;&#x000a0;25</td><td>8</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="s0040"><label>3</label><title>Results and discussion</title><sec id="s0045"><label>3.1</label><title>Virtual screening of drug-like compounds:</title><p id="p0050">A set of 75 FDA approved antiviral drugs and 263 phytochemicals belonging to different classes such as prenol lipids, flavonoids, indoles and derivatives, alkaloids, lignans, organooxygen compounds etc. were used for the present study. Since the FDA approved drugs have already undergone the preclinical and clinical trials and tested safe in patients, the drugs were not tested again using <italic>in silico</italic> drug-like filters. While plant-derived compounds are much safer to use with fewer adverse effects, we subjected them into virtual screening protocol to reduce the drug-attrition rate. We used the rule of five (ROF) and Veber&#x02019;s rule filters to test the oral bioavailability of the compounds. According to ROF, a compound is considered to be orally bioactive if their physicochemical properties lie within the safe limits (molecular weight&#x000a0;&#x02264;&#x000a0;500&#x000a0;Da, hydrogen bond donors&#x000a0;&#x02264;&#x000a0;5, hydrogen bond acceptors&#x000a0;&#x02264;&#x000a0;10, and an octanol&#x02013;water partition coefficient log P&#x000a0;&#x02264;&#x000a0;5) (<xref rid="b0105" ref-type="bibr">Lipinski, 2004</xref>). Veber's rule states that a good oral bioavailable compound possesses number of rotatable bonds&#x000a0;&#x02264;&#x000a0;10 and topological polar surface area&#x000a0;&#x02264;&#x000a0;140&#x000a0;&#x000c5;<sup>2</sup> (<xref rid="b0165" ref-type="bibr">Veber et al., 2002</xref>). Further, the molecules were also tested for <italic>in silico</italic> toxicity studies. Out of 263 phytochemicals, 46 molecules were found to be orally bioactive, non-tumorigenic, non-mutagenic, non-irritant and without any side effects on reproductive health. Thus, these 46 phytochemicals and 75 FDA approved drugs were tested further for their inhibitory potential against the three enzyme targets (<xref rid="t0010" ref-type="table">Table 2</xref>, <xref rid="t0015" ref-type="table">Table 3</xref>
).<table-wrap position="float" id="t0010"><label>Table 2</label><caption><p>List of FDA approved antiviral drugs selected for molecular docking studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Drugs</th><th>DrugBank ID</th><th>Therapy</th></tr></thead><tbody><tr><td>Ombitasvir</td><td>DB09296</td><td>Chronic Hepatitis C</td></tr><tr><td>Elbasvir</td><td>DB11574</td><td>Chronic Hepatitis C</td></tr><tr><td><underline>Sofosbuvir</underline></td><td>DB08934</td><td>Chronic Hepatitis C</td></tr><tr><td>Ledipasvir</td><td>DB09027</td><td>Chronic Hepatitis C</td></tr><tr><td>Famciclovir</td><td>DB00426</td><td>Herpes virus infections</td></tr><tr><td>Simeprevir</td><td>DB06290</td><td>Chronic hepatitis C virus</td></tr><tr><td>Lopinavir</td><td>DB01601</td><td>Human immunodeficiency virus type 1 (HIV-1) infection.</td></tr><tr><td>Tecovirimat</td><td>DB12020</td><td>Smallpox</td></tr><tr><td>Oseltamivir</td><td>DB00198</td><td>Influenza viruses A and B infections</td></tr><tr><td>Baloxavir marboxil</td><td>DB13997</td><td>Influenza A and influenza B infections</td></tr><tr><td>Didanosine</td><td>DB00900</td><td>HIV infection</td></tr><tr><td>Bictegravir</td><td>DB11799</td><td>HIV-1 and HIV-2 infection</td></tr><tr><td>Adefovir dipivoxil</td><td>DB00718</td><td>Hepatitis B</td></tr><tr><td>Zalcitabine</td><td>DB00943</td><td>HIV infection</td></tr><tr><td>Emtricitabine</td><td>DB00879</td><td>HIV-1 infection</td></tr><tr><td>Zidovudine</td><td>DB00495</td><td>HIV infection</td></tr><tr><td>Darunavir</td><td>DB01264</td><td>HIV-1 infection</td></tr><tr><td>Nevirapine</td><td>DB00238</td><td>HIV-1 infection and AIDS.</td></tr><tr><td>Valganciclovir</td><td>DB01610</td><td>Cytomegalovirus infections</td></tr><tr><td>Nelfinavir</td><td>DB00220</td><td>HIV infection</td></tr><tr><td>Foscarnet</td><td>DB00529</td><td>cytomegalovirus retinitis, HIV infection</td></tr><tr><td>Boceprevir</td><td>DB08873</td><td>Chronic Hepatitis C</td></tr><tr><td>Inosine pranobex</td><td>DB13156</td><td>Viral infection</td></tr><tr><td>Dolutegravir</td><td>DB08930</td><td>HIV-1 infection</td></tr><tr><td>Abacavir</td><td>DB01048</td><td>HIV infection and AIDS.</td></tr><tr><td>Edoxudine</td><td>DB13421</td><td>Herpes simplex virus type 1 and 2 infection</td></tr><tr><td>Ribavirin</td><td>DB00811</td><td>Hepatitis C and viral hemorrhagic fevers</td></tr><tr><td>Elvitegravir</td><td>DB09101</td><td>HIV-1 infection</td></tr><tr><td>Amantadine</td><td>DB00915</td><td>Influenza A infection</td></tr><tr><td>Vidarabine</td><td>DB00194</td><td>Herpes viruses, the vaccinia virus and varicella zoster virus infection</td></tr><tr><td>Daclatasvir</td><td>DB09102</td><td>Hepatitis C Virus (HCV) infection</td></tr><tr><td>Tenofovir alafenamide</td><td>DB09299</td><td>Chronic hepatitis B and HIV-1 infection</td></tr><tr><td>Ritonavir</td><td>DB00503</td><td>HIV infection</td></tr><tr><td>Trifluridine</td><td>DB00432</td><td>Keratoconjunctivitis and recurrent epithelial keratitis</td></tr><tr><td>Zanamivir</td><td>DB00558</td><td>Influenza A and B virus infection</td></tr><tr><td>Acyclovir</td><td>DB00787</td><td>Herpes simplex, <italic>Varicella zoster</italic>, herpes zoster infection</td></tr><tr><td>Ganciclovir</td><td>DB01004</td><td>AIDS-associated cytomegalovirus infections.</td></tr><tr><td>Entecavir</td><td>DB00442</td><td>Hepatitis B infection</td></tr><tr><td>Raltegravir</td><td>DB06817</td><td>HIV infection</td></tr><tr><td>Doravirine</td><td>DB12301</td><td>HIV-1 Infection</td></tr><tr><td>Pibrentasvir</td><td>DB13878</td><td>Hepatitis C virus (HCV) infection</td></tr><tr><td>Fosamprenavir</td><td>DB01319</td><td>HIV infection</td></tr><tr><td>Glecaprevir</td><td>DB13879</td><td>HCV infection</td></tr><tr><td>Tipranavir</td><td>DB00932</td><td>HIV infection</td></tr><tr><td>Etravirine</td><td>DB06414</td><td>HIV-1 infection</td></tr><tr><td>Amprenavir</td><td>DB00701</td><td>HIV infection.</td></tr><tr><td>Letermovir</td><td>DB12070</td><td>Cytomegalovirus (CMV) infection</td></tr><tr><td>Favipiravir</td><td>DB12466</td><td>Influenza</td></tr><tr><td>Idoxuridine</td><td>DB00249</td><td>Herpes simplex virus (HSV) infection</td></tr><tr><td>Rimantadine</td><td>DB00478</td><td>Influenza.</td></tr><tr><td>Tromantadine</td><td>DB13288</td><td>Herpes zoster and simplex virus infection</td></tr><tr><td>Telaprevir</td><td>DB05521</td><td>Chronic Hepatitis C</td></tr><tr><td>Dasabuvir</td><td>DB09183</td><td>Chronic Hepatitis C</td></tr><tr><td>Grazoprevir</td><td>DB11575</td><td>Chronic Hepatitis C</td></tr><tr><td>Docosanol</td><td>DB00632</td><td>HSV infection</td></tr><tr><td>Penciclovir</td><td>DB00299</td><td>HSV infections</td></tr><tr><td>Velpatasvir</td><td>DB11613</td><td>chronic Hepatitis C</td></tr><tr><td>Tenofovir disoproxil</td><td>DB00300</td><td>HIV infection and Hepatitis B</td></tr><tr><td>Cidofovir</td><td>DB00369</td><td>CMV retinitis</td></tr><tr><td>Voxilaprevir</td><td>DB12026</td><td>Chronic Hepatitis C</td></tr><tr><td>Asunaprevir</td><td>DB11586</td><td>HCV infection</td></tr><tr><td>Valaciclovir</td><td>DB00577</td><td>Hepatitis, HIV, and cytomegalovirus infection</td></tr><tr><td>Efavirenz</td><td>DB00625</td><td>HIV-1 infection</td></tr><tr><td>Peramivir</td><td>DB06614</td><td>Influenza A/B.</td></tr><tr><td>Brivudine</td><td>DB03312</td><td>Herpes zoster.</td></tr><tr><td>Telbivudine</td><td>DB01265</td><td>Hepatitis B virus infection</td></tr><tr><td>Maraviroc</td><td>DB04835</td><td>HIV infection</td></tr><tr><td>Stavudine</td><td>DB00649</td><td>HIV infection</td></tr><tr><td>Paritaprevir</td><td>DB09297</td><td>Chronic Hepatitis C</td></tr><tr><td>Indinavir</td><td>DB00224</td><td>HIV infection</td></tr><tr><td>Lamivudine</td><td>DB00709</td><td>HIV-1 and hepatitis B virus (HBV) infection</td></tr><tr><td>Atazanavir</td><td>DB01072</td><td>HIV infection</td></tr><tr><td>Rilpivirine</td><td>DB08864</td><td>HIV-1 infection</td></tr><tr><td>Delavirdine</td><td>DB00705</td><td>HIV-1.infection</td></tr><tr><td>Saquinavir</td><td>DB01232</td><td>HIV-1 and HIV-2 infection</td></tr></tbody></table></table-wrap><table-wrap position="float" id="t0015"><label>Table 3</label><caption><p>List of phytochemicals selected for the docking studies (MW: molecular weight; cLogP: octanol&#x02013;water partition coefficient; cLogS: aqueous solubility at 25&#x000b0; and pH&#x000a0;=&#x000a0;7.5; HBA: hydrogen bond acceptor; HBD: hydrogen bond donor; TPSA (&#x000c5;<sup>2</sup>): Topological polar surface area; RB: rotatable bonds).</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Molecule Name</th><th>CASID/CHEMSPIDER/CID</th><th>Class</th><th>MW</th><th>cLogP</th><th>cLogS</th><th>HBA</th><th>HBD</th><th>TPSA</th><th>RB</th><th>Druglikeness</th></tr></thead><tbody><tr><td>Heterophylloidine</td><td>78174&#x02013;97-7</td><td>Prenol lipids</td><td>383.486</td><td>2.2205</td><td>&#x02212;3.41</td><td>5</td><td>0</td><td>63.68</td><td>2</td><td>2.7882</td></tr><tr><td>Arjunolone</td><td>82178&#x02013;34-5</td><td>Flavonoids</td><td>284.266</td><td>2.6114</td><td>&#x02212;3.17</td><td>5</td><td>2</td><td>75.99</td><td>2</td><td>0.40331</td></tr><tr><td>Rosicine</td><td>95690&#x02013;65-6</td><td>Indoles and derivatives</td><td>324.379</td><td>0.8137</td><td>&#x02212;3.091</td><td>5</td><td>1</td><td>54.1</td><td>2</td><td>2.2389</td></tr><tr><td>Asparagamine A</td><td>156798&#x02013;15-1</td><td>Organooxygen compounds</td><td>385.458</td><td>2.1085</td><td>&#x02212;3.634</td><td>6</td><td>0</td><td>57.23</td><td>3</td><td>0.7051</td></tr><tr><td>Piscrocin B</td><td>752225&#x02013;57-3</td><td>Heteroaromatic compounds</td><td>198.173</td><td>&#x02212;0.1119</td><td>&#x02212;1.262</td><td>5</td><td>3</td><td>90.9</td><td>2</td><td>0.20569</td></tr><tr><td>6-Acetylheteratisine</td><td>10,246,449</td><td>Quinolidines</td><td>433.543</td><td>1.1579</td><td>&#x02212;3.186</td><td>7</td><td>1</td><td>85.3</td><td>4</td><td>4.6497</td></tr><tr><td>Gummadiol</td><td>10,308,017</td><td>Furanoid lignans</td><td>386.355</td><td>2.0507</td><td>&#x02212;3.752</td><td>8</td><td>2</td><td>95.84</td><td>2</td><td>0.1606</td></tr><tr><td>Vidolicine</td><td>28,288,759</td><td>Indoles and derivatives</td><td>352.433</td><td>1.5661</td><td>&#x02212;3.47</td><td>5</td><td>1</td><td>54.1</td><td>3</td><td>2.5754</td></tr><tr><td>19-Hydroxy-11-methoxytabersonine</td><td>57,619,488</td><td>Plumeran-type alkaloids</td><td>382.458</td><td>1.3822</td><td>&#x02212;3.246</td><td>6</td><td>2</td><td>71.03</td><td>4</td><td>0.90699</td></tr><tr><td>Boldine</td><td>10,154</td><td>Aporphines</td><td>327.379</td><td>2.7882</td><td>&#x02212;3.129</td><td>5</td><td>2</td><td>62.16</td><td>2</td><td>4.6712</td></tr><tr><td>Indoline</td><td>10,328</td><td>Indoles and derivatives</td><td>119.166</td><td>1.3351</td><td>&#x02212;2.025</td><td>1</td><td>1</td><td>12.03</td><td>0</td><td>0.19917</td></tr><tr><td>Tubotaiwine</td><td>100,004</td><td>Strychnos alkaloids</td><td>324.423</td><td>2.3452</td><td>&#x02212;3.568</td><td>4</td><td>1</td><td>41.57</td><td>3</td><td>1.5804</td></tr><tr><td>Cinchonidine</td><td>101,744</td><td>Cinchona alkaloids</td><td>294.397</td><td>2.6804</td><td>&#x02212;3.079</td><td>3</td><td>1</td><td>36.36</td><td>3</td><td>0.88095</td></tr><tr><td>Tryptoline</td><td>107,838</td><td>Indoles and derivatives</td><td>172.23</td><td>1.2188</td><td>&#x02212;2.39</td><td>2</td><td>2</td><td>27.82</td><td>0</td><td>1.1795</td></tr><tr><td>Alloyohimbine</td><td>120,716</td><td>Yohimbine alkaloids</td><td>354.448</td><td>2.3512</td><td>&#x02212;3.065</td><td>5</td><td>2</td><td>65.56</td><td>2</td><td>1.5035</td></tr><tr><td>Cuscohygrine</td><td>1,201,543</td><td>Alkaloids and derivatives</td><td>224.347</td><td>1.2932</td><td>&#x02212;1.22</td><td>3</td><td>0</td><td>23.55</td><td>4</td><td>4.2839</td></tr><tr><td>Sebiferine</td><td>10,405,046</td><td>Phenanthrenes and derivatives</td><td>341.406</td><td>1.9462</td><td>&#x02212;2.753</td><td>5</td><td>0</td><td>48</td><td>3</td><td>5.7459</td></tr><tr><td>Condylocarpine</td><td>10,914,255</td><td>Strychnos alkaloids</td><td>322.407</td><td>2.2523</td><td>&#x02212;3.304</td><td>4</td><td>1</td><td>41.57</td><td>2</td><td>0.29114</td></tr><tr><td>19,20-Dihydroakuammicine</td><td>11,023,792</td><td>Alkaloids and derivatives</td><td>324.423</td><td>2.3452</td><td>&#x02212;3.568</td><td>4</td><td>1</td><td>41.57</td><td>3</td><td>2.1615</td></tr><tr><td>Lochnericine</td><td>11,382,599</td><td>Aspidospermatan-type alkaloids</td><td>352.433</td><td>1.5996</td><td>&#x02212;3.538</td><td>5</td><td>1</td><td>54.1</td><td>3</td><td>2.3885</td></tr><tr><td>3-Isoajmalicine</td><td>11,416,867</td><td>Yohimbine alkaloids</td><td>352.433</td><td>2.2674</td><td>&#x02212;3.141</td><td>5</td><td>1</td><td>54.56</td><td>2</td><td>2.6043</td></tr><tr><td>Vindolidin</td><td>11,618,751</td><td>Plumeran-type alkaloids</td><td>426.511</td><td>1.3936</td><td>&#x02212;3.098</td><td>7</td><td>1</td><td>79.31</td><td>5</td><td>3.2845</td></tr><tr><td>Vincapusine</td><td>11,646,359</td><td>Alkaloids and derivatives</td><td>368.432</td><td>2.6409</td><td>&#x02212;2.695</td><td>6</td><td>1</td><td>63.93</td><td>3</td><td>2.2856</td></tr><tr><td>Epibubbialine</td><td>11,830,997</td><td>Azaspirodecane derivatives</td><td>221.255</td><td>&#x02212;0.1874</td><td>&#x02212;1.424</td><td>4</td><td>1</td><td>49.77</td><td>0</td><td>1.6204</td></tr><tr><td>Vindoline</td><td>11,953,805</td><td>Plumeran-type alkaloids</td><td>456.537</td><td>1.3236</td><td>&#x02212;3.116</td><td>8</td><td>1</td><td>88.54</td><td>6</td><td>3.2845</td></tr><tr><td>1,2-Dihydrovomilenine</td><td>11,953,964</td><td>Ajmaline-sarpagine alkaloids</td><td>352.433</td><td>1.8244</td><td>&#x02212;3.654</td><td>5</td><td>2</td><td>61.8</td><td>2</td><td>1.1872</td></tr><tr><td>Pericyclivine</td><td>11,969,544</td><td>Macroline alkaloids</td><td>322.407</td><td>2.8635</td><td>&#x02212;3.038</td><td>4</td><td>1</td><td>45.33</td><td>2</td><td>0.20237</td></tr><tr><td>Lycoctonine</td><td>11,972,492</td><td>Prenol lipids</td><td>467.601</td><td>&#x02212;0.1645</td><td>&#x02212;1.824</td><td>8</td><td>3</td><td>100.85</td><td>6</td><td>0.56009</td></tr><tr><td>Cathanneine</td><td>12,302,545</td><td>Aspidospermatan-type alkaloids</td><td>426.511</td><td>1.3713</td><td>&#x02212;3.408</td><td>7</td><td>0</td><td>68.31</td><td>5</td><td>2.5051</td></tr><tr><td>Anahygrine</td><td>12,306,778</td><td>Alkaloids and derivatives</td><td>224.347</td><td>1.3823</td><td>&#x02212;1.852</td><td>3</td><td>1</td><td>32.34</td><td>4</td><td>3.0573</td></tr><tr><td>Tabernaemontanin</td><td>12,309,360</td><td>Vobasan alkaloids</td><td>354.448</td><td>2.6197</td><td>&#x02212;3.678</td><td>5</td><td>1</td><td>62.4</td><td>3</td><td>3.1533</td></tr><tr><td>4-Methoxynorsecurinine</td><td>101,091,319</td><td>Pyrrolizidines</td><td>233.266</td><td>&#x02212;0.0349</td><td>&#x02212;1.324</td><td>4</td><td>0</td><td>38.77</td><td>1</td><td>1.5563</td></tr><tr><td>Akuammicine</td><td>101,281,350</td><td>Strychnos alkaloids</td><td>322.407</td><td>2.2523</td><td>&#x02212;3.304</td><td>4</td><td>1</td><td>41.57</td><td>2</td><td>0.87991</td></tr><tr><td>Heterophyllisine</td><td>101,289,617</td><td>Quinolidines</td><td>375.507</td><td>1.5254</td><td>&#x02212;3.175</td><td>5</td><td>1</td><td>59</td><td>2</td><td>4.4531</td></tr><tr><td>Germacranolide</td><td>101,616,641</td><td>Prenol lipids</td><td>266.336</td><td>2.1659</td><td>&#x02212;2.371</td><td>4</td><td>2</td><td>66.76</td><td>0</td><td>1.5629</td></tr><tr><td>Isoajmaline</td><td>101,624,670</td><td>Ajmaline-sarpagine alkaloids</td><td>326.438</td><td>1.791</td><td>&#x02212;3.484</td><td>4</td><td>2</td><td>46.94</td><td>1</td><td>3.4513</td></tr><tr><td>Hetidine</td><td>101,685,340</td><td>Prenol lipids</td><td>357.448</td><td>0.8838</td><td>&#x02212;2.601</td><td>5</td><td>2</td><td>77.84</td><td>0</td><td>2.8009</td></tr><tr><td>Catharosine</td><td>101,686,461</td><td>Plumeran-type alkaloids</td><td>384.474</td><td>0.909</td><td>&#x02212;2.688</td><td>6</td><td>2</td><td>73.24</td><td>3</td><td>3.3742</td></tr><tr><td>Fluorocarpamine</td><td>101,688,177</td><td>Carboxylic acids and derivatives</td><td>339.414</td><td>1.8706</td><td>&#x02212;3.095</td><td>5</td><td>1</td><td>58.64</td><td>2</td><td>0.97774</td></tr><tr><td>Ajmalicidine</td><td>101,927,009</td><td>Indoles and derivatives</td><td>370.447</td><td>3.0403</td><td>&#x02212;3.438</td><td>6</td><td>1</td><td>63.93</td><td>2</td><td>2.2403</td></tr><tr><td>Hetisinone</td><td>101,930,090</td><td>Prenol lipids</td><td>327.423</td><td>1.0959</td><td>&#x02212;2.903</td><td>4</td><td>2</td><td>60.77</td><td>0</td><td>0.86256</td></tr><tr><td>Rhazimol</td><td>101,986,486</td><td>Corynanthean-type alkaloids</td><td>338.406</td><td>0.2205</td><td>&#x02212;2.55</td><td>5</td><td>2</td><td>73.13</td><td>2</td><td>2.6104</td></tr><tr><td>18-Hydroxy-3-epi-alpha-yohimbine</td><td>102,004,710</td><td>Yohimbine alkaloids</td><td>370.447</td><td>1.4991</td><td>&#x02212;2.666</td><td>6</td><td>3</td><td>85.79</td><td>2</td><td>2.3334</td></tr><tr><td>Sarpagine</td><td>102,090,391</td><td>Macroline alkaloids</td><td>310.396</td><td>2.4395</td><td>&#x02212;2.632</td><td>4</td><td>3</td><td>59.49</td><td>1</td><td>2.0345</td></tr><tr><td>Velbanamine</td><td>102,399,433</td><td>Indoles and derivatives</td><td>298.428</td><td>3.3453</td><td>&#x02212;3.206</td><td>3</td><td>2</td><td>39.26</td><td>1</td><td>3.5116</td></tr><tr><td>Catharosine</td><td>2564&#x02013;23-0</td><td>Plumeran-type alkaloids</td><td>384.474</td><td>0.909</td><td>&#x02212;2.688</td><td>6</td><td>2</td><td>73.24</td><td>3</td><td>3.3742</td></tr></tbody></table></table-wrap></p></sec><sec id="s0050"><label>3.2</label><title>Top ranked lead molecules for SARS-CoV-2 3CL<sup>pro</sup> from a set of phytochemicals and FDA approved drugs:</title><p id="p0055">The top five leads-102004710 (18-Hydroxy-3-epi-alpha-yohimbine), 120,716 (Alloyohimbine), 10,308,017 (Gummadiol), 156798&#x02013;15-1 (Asparagamine A) and 11,646,359 (Vincapusine) for SARS-CoV-2 3CL<sup>pro</sup> obtained using molecular docking studies of phytochemicals showed binding energies of &#x02212;8.1&#x000a0;kcal/mol, &#x02212;8.0&#x000a0;kcal/mol, &#x02212;7.8&#x000a0;kcal/mol, &#x02212;7.6&#x000a0;kcal/mol and &#x02212;7.5&#x000a0;kcal/mol respectively. Molecular docking of FDA approved antiviral drugs yielded top 5 lead molecules-DB06290 (Simeprevir), DB09027 (Ledipasvir), DB09297 (Paritaprevir), DB13879 (Glecaprevir) and DB09102 (Daclatasvir) which showed binding energies of &#x02212;9.7&#x000a0;kcal/mol, &#x02212;9.3&#x000a0;kcal/mol, &#x02212;9.3&#x000a0;kcal/mol, &#x02212;9.3&#x000a0;kcal/mol and &#x02212;9.2&#x000a0;kcal/mol respectively. The control &#x003b1;-ketoamide 13a inhibitor (O6K) displayed binding energy of &#x02212;7.2&#x000a0;kcal/mol. All the lead compounds showed stable interactions with the target through a good number of hydrogen bonds as well as hydrophobic interactions except for 156798&#x02013;15-1 (Asparagamine A) which exhibited only hydrophobic interactions. Interestingly, compared to the phytochemicals the FDA-approved antiviral drugs showed higher binding affinities to the target. Further, the lead molecules-10308017 (Gummadiol), 11,646,359 (Vincapusine) and DB13879 (Glecaprevir) showed the potential antiviral activity through hydrogen bond interactions with either His41 or Cys145, both of the residues constitute the catalytic dyad of SARS-CoV-2 3CL<sup>pro</sup> enzyme.</p></sec><sec id="s0055"><label>3.3</label><title>Top ranked lead molecules for SARS-CoV 3CL<sup>pro</sup> from a set of phytochemicals and FDA approved drugs:</title><p id="p0060">Among the phytochemicals, top 5 leads-120716 (Alloyohimbine), 10,308,017 (Gummadiol), 11,646,359 (Vincapusine), 82178-34-5 (Arjunolone), 102,004,710 (18-Hydroxy-3-epi-alpha-yohimbine) showed binding energies of &#x02212;9.0&#x000a0;kcal/mol, &#x02212;8.4&#x000a0;kcal/mol, &#x02212;8.3&#x000a0;kcal/mol, &#x02212;8.1&#x000a0;kcal/mol and &#x02212;8.0&#x000a0;kcal/mol respectively. Using molecular docking of FDA approved antiviral drugs, top 5 leads-DB13879 (Glecaprevir), DB13878 (Pibrentasvir), DB01072 (Atazanavir), DB09102 (Daclatasvir) and DB11574 (Elbasvir) were shortlisted which displayed binding energies of &#x02212;9.7&#x000a0;kcal/mol, &#x02212;9.3&#x000a0;kcal/mol, &#x02212;9.2&#x000a0;kcal/mol, &#x02212;9.2&#x000a0;kcal/mol and &#x02212;8.8&#x000a0;kcal/mol respectively. The molecular binding between these lead compounds and the target is strengthened by a good number of hydrogen bonds and hydrophobic interactions. The leads which displayed hydrogen bond interactions with the catalytic residues-His41 and Cys145 include DB13879 (Glecaprevir), DB11574 (Elbasvir), 10,308,017 (Gummadiol) and 102,004,710 (18-Hydroxy-3-epi-alpha-yohimbine). The control, SG85 inhibitor (G85) showed binding energy of &#x02212;8.0&#x000a0;kcal/mol with the enzyme target.</p></sec><sec id="s0060"><label>3.4</label><title>Top ranked lead molecules for MERS-CoV 3CL<sup>pro</sup> from a set of phytochemicals and FDA approved drugs:</title><p id="p0065">Few lead compounds were also identified for MERS-CoV 3CL<sup>pro</sup> using molecular docking of phytochemicals and the binding energies of top 5 leads-11646359 (Vincapusine), 120,716 (Alloyohimbine), 10,308,017 (Gummadiol), 11,969,544 (Pericyclivine) and 28,288,759 (Vidolicine) were &#x02212;9.8&#x000a0;kcal/mol, &#x02212;8.6&#x000a0;kcal/mol, &#x02212;8.4&#x000a0;kcal/mol, &#x02212;8.4&#x000a0;kcal/mol and &#x02212;8.3&#x000a0;kcal/mol respectively. Among, the FDA approved antiviral drugs, the top 5 leads-DB01072 (Atazanavir), DB06817 (Raltegravir), DB09296 (Ombitasvir), DB08864 (Rilpivirine) and DB09297 (Paritaprevir) scored binding energies of &#x02212;9.1&#x000a0;kcal/mol, &#x02212;9.1&#x000a0;kcal/mol, &#x02212;9.0&#x000a0;kcal.mol, &#x02212;8.7&#x000a0;kcal/mol and &#x02212;8.7&#x000a0;kcal/mol respectively. The control, GC813 inhibitor (AW4) showed binding energy of &#x02212;8.0&#x000a0;kcal/mol. All the lead compounds established both a good number of hydrogen bonds as well as hydrophobic interactions with the target except 28,288,759 which exhibited only hydrophobic interactions. The lead molecules-DB06817 (Raltegravir), 120,716 (Alloyohimbine) and 11,969,544 (Pericyclivine) established hydrogen bond interactions with either His41 or Cys148 or both (catalytic dyad) which may explain their mode of inhibition against the enzyme target.</p></sec><sec id="s0065"><label>3.5</label><title>Common lead molecules as potential dual or triple inhibitors of the enzyme targets</title><p id="p0070">Among the FDA approved antiviral drugs, we found that DB13879 (Glecaprevir) and DB09102 (Daclatasvir) can be potential leads for dual inhibition of SARS-CoV-2 3CL<sup>pro</sup> (<xref rid="f0005" ref-type="fig">Fig. 1</xref>
A, B) and SARS-CoV 3CL<sup>pro</sup> as they were common top 5 leads. The lead molecule DB09297 (Paritaprevir) can be explored as a dual inhibitor of SARS-CoV-2 3CL<sup>pro</sup> (<xref rid="f0005" ref-type="fig">Fig. 1</xref>C) and MERS-CoV 3CL<sup>pro</sup> and DB01072 (Atazanavir) can be used as an inhibitor for dual inhibition of SARS-CoV 3CL<sup>pro</sup> and MERS-CoV 3CL<sup>pro</sup>. While Glecaprevir, Daclatasvir and Paritaprevir have been used against chronic hepatitis C (<xref rid="b0045" ref-type="bibr">For the Study of the Liver (KASL, K.A., others, 2018</xref>, <xref rid="b0070" ref-type="bibr">H&#x000e9;zode, 2018</xref>), Atazanavir (HIV-1 protease inhibitor) is primarily used for the treatment of HIV infection (<xref rid="b0040" ref-type="bibr">Eckhardt and Gulick, 2017</xref>). Interestingly, we found that the phytochemicals 11,646,359 (Vincapusine), 120,716 (Alloyohimbine) and 10,308,017 (Gummadiol) were common top 5 leads among the three targets and therefore, these phytochemicals can be used as triple inhibitors of SARS-CoV-2 3CL<sup>pro</sup> (<xref rid="f0010" ref-type="fig">Fig. 2</xref>
A&#x02013;C), SARS-CoV 3CL<sup>pro</sup> and MERS-CoV 3CL<sup>pro</sup>. The phytochemical 102,004,710 (18-Hydroxy-3-epi-alpha-yohimbine) was identified to be a potential dual inhibitor of SARS-CoV-2 3CL<sup>pro</sup> and SARS-CoV 3CL<sup>pro</sup>. Vinacapusine is a &#x003b2;-amino alcohol-type alkaloid extracted from leaves of <italic>Catharanthus pusillus</italic>, a traditional medicinal plant of India believed to possess oncolytic properties (<xref rid="b0080" ref-type="bibr">Khare, 2007</xref>). Gummadiol belongs to the class of Furanoid lignans which can be extracted from <italic>Gmelina arborea</italic> (<xref rid="b0015" ref-type="bibr">Anjaneyulu et al., 1975</xref>, <xref rid="b0140" ref-type="bibr">Pathala et al., 2015</xref>). Alloyohimbine and 18-Hydroxy-3-epi-alpha-yohimbine are alkaloids which are isomeric forms of yohimbine, an alkaloid extracted from the bark of the tree <italic>Pausinystalia yohimbe</italic> and has been traditionally used for the treatment of sexual disorders (<xref rid="b0010" ref-type="bibr">Anad&#x000f3;n et al., 2016</xref>). However, the bioactivity of these compounds against viral infections have not been reported till date to the best of our knowledge and therefore these are novel phytochemical leads which could be further explored against coronavirus infections in humans. The key findings from the present study has been illustrated with <xref rid="f0015" ref-type="fig">Fig. 3</xref>
.<fig id="f0005"><label>Fig. 1</label><caption><p>The binding poses and LigPlot&#x000a0;+&#x000a0;results showing molecular interaction between SARS-CoV-2 3CL<sup>pro</sup> and lead molecules-(FDA approved antiviral drugs) (A) DB13879 (Glecaprevir) (B) DB09102 (Daclatasvir) (C) DB09297 (Paritaprevir). The hydrophobic interacting residues are indicated by red arcs with spikes and the green dashed lines with the bond distance correspond to hydrogen bonds.</p></caption><graphic xlink:href="gr1_lrg"/></fig><fig id="f0010"><label>Fig. 2</label><caption><p>The binding poses and LigPlot&#x000a0;+&#x000a0;results showing molecular interaction between SARS-CoV-2 3CLpro and lead molecules-(Phytochemicals) (A) 11,646,359 (Vincapusine) (B) 120,716 (Alloyohimbine) (C) 10,308,017 (Gummadiol). The hydrophobic interacting residues are indicated by red arcs with spikes and the green dashed lines with the bond distance correspond to hydrogen bonds.</p></caption><graphic xlink:href="gr2_lrg"/></fig><fig id="f0015"><label>Fig. 3</label><caption><p>A graphical summary illustrating the key findings from the present study.</p></caption><graphic xlink:href="gr3_lrg"/></fig></p></sec></sec><sec id="s0070"><label>4</label><title>Conclusion</title><p id="p0075">The present work is an <italic>in silico</italic> attempt to propose lead molecules as potential inhibitors of coronavirus 3CL<sup>pro</sup> enzyme. Our study unravels new chemical entities from a repertoire of phytochemicals and FDA approved drugs that could be repurposed for treatment of coronavirus infection in humans. The leads suggested from this study could offer new candidate molecules in the drug discovery pipeline for the treatment and management of the disease. The current work is limited by small datasets and therefore, it would be worth exploring new chemical databases with big ligand sets for virtual screening procedure for identification of novel inhibitors against the target enzyme. A combined molecular docking and molecular dynamics simulation approach could be envisaged which would further provide useful mechanistic insights into the binding modes of inhibitions at the atomic level. Further research work is necessary to establish the inhibitory activity of the identified FDA approved lead molecules against the coronavirus 3CL<sup>pro</sup> enzyme through <italic>in vitro</italic> and <italic>in vivo</italic> experiments.</p></sec><sec sec-type="COI-statement"><title>Declaration of Competing Interest</title><p id="p0080">The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</p></sec></body><back><ref-list id="bi005"><title>References</title><ref id="b0005"><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Abd El-Aziz</surname><given-names>T.M.</given-names></name><name><surname>Stockand</surname><given-names>J.D.</given-names></name></person-group><article-title>Recent progress and challenges in drug development against COVID-19 coronavirus (SARS-CoV-2)-an update on the status</article-title><source>Infect. Genet. Evol.</source><volume>83</volume><year>2020</year><object-id pub-id-type="publisher-id">104327</object-id></element-citation></ref><ref id="b0010"><mixed-citation publication-type="other" id="h0010">Anad&#x000f3;n, A., Mart&#x000ed;nez-Larra&#x000f1;aga, M.R., Ares, I., Mart&#x000ed;nez, M.A., 2016. Chapter 60 - Interactions between Nutraceuticals/Nutrients and Therapeutic Drugs, in: Gupta, R.C. (Ed.), Nutraceuticals. Academic Press, Boston, pp. 855&#x02013;874. https://doi.org/https://doi.org/10.1016/B978-0-12-802147-7.00060-7.</mixed-citation></ref><ref id="b0015"><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Anjaneyulu</surname><given-names>A.S.R.</given-names></name><name><surname>Rao</surname><given-names>A.M.</given-names></name><name><surname>Rao</surname><given-names>V.K.</given-names></name><name><surname>Row</surname><given-names>L.R.</given-names></name><name><surname>Pelter</surname><given-names>A.</given-names></name><name><surname>Ward</surname><given-names>R.S.</given-names></name></person-group><article-title>The structure of gummadiol-a lignan hemi-acetal</article-title><source>Tetrahedron Lett.</source><volume>16</volume><year>1975</year><fpage>1803</fpage><lpage>1806</lpage></element-citation></ref><ref id="b0020"><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Bredenbeek</surname><given-names>P.J.</given-names></name><name><surname>Pachuk</surname><given-names>C.J.</given-names></name><name><surname>Noten</surname><given-names>A.F.H.</given-names></name><name><surname>Charit&#x000e9;</surname><given-names>J.</given-names></name><name><surname>Luytjes</surname><given-names>W.</given-names></name><name><surname>Weiss</surname><given-names>S.R.</given-names></name><name><surname>Spaan</surname><given-names>W.J.M.</given-names></name></person-group><article-title>The primary structure and expression of the second open reading frame of the polymerase gene of the coronavirus MHV-A59; a highly conserved polymerase is expressed by an efficient ribosomal frameshifting mechanism</article-title><source>Nucleic Acids Res.</source><volume>18</volume><year>1990</year><fpage>1825</fpage><lpage>1832</lpage><pub-id pub-id-type="pmid">2159623</pub-id></element-citation></ref><ref id="b0025"><mixed-citation publication-type="other" id="h0025">Brian, D.A., Baric, R.S., 2005. Coronavirus genome structure and replication, in: Coronavirus Replication and Reverse Genetics. Springer, pp. 1&#x02013;30.</mixed-citation></ref><ref id="b0030"><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>J.</given-names></name><name><surname>Li</surname><given-names>F.</given-names></name><name><surname>Shi</surname><given-names>Z.-L.</given-names></name></person-group><article-title>Origin and evolution of pathogenic coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><volume>17</volume><year>2019</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">30531947</pub-id></element-citation></ref><ref id="b0035"><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Dhama</surname><given-names>K.</given-names></name><name><surname>Sharun</surname><given-names>K.</given-names></name><name><surname>Tiwari</surname><given-names>R.</given-names></name><name><surname>Dadar</surname><given-names>M.</given-names></name><name><surname>Malik</surname><given-names>Y.S.</given-names></name><name><surname>Singh</surname><given-names>K.P.</given-names></name><name><surname>Chaicumpa</surname><given-names>W.</given-names></name></person-group><article-title>COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics</article-title><source>Hum. Vaccin. Immunother.</source><year>2020</year><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="b0040"><mixed-citation publication-type="other" id="h0040">Eckhardt, B.J., Gulick, R.M., 2017. 152 - Drugs for HIV Infection, in: Cohen, J., Powderly, W.G., Opal, S.M. (Eds.), Infectious Diseases (Fourth Edition). Elsevier, pp. 1293-1308.e2. https://doi.org/https://doi.org/10.1016/B978-0-7020-6285-8.00152-0.</mixed-citation></ref><ref id="b0045"><mixed-citation publication-type="other" id="h0045">For the Study of the Liver (KASL, K.A., others, 2018. 2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C. Clin. Mol. Hepatol. 24, 169-229.</mixed-citation></ref><ref id="b0050"><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Forni</surname><given-names>D.</given-names></name><name><surname>Cagliani</surname><given-names>R.</given-names></name><name><surname>Clerici</surname><given-names>M.</given-names></name><name><surname>Sironi</surname><given-names>M.</given-names></name></person-group><article-title>Molecular evolution of human coronavirus genomes</article-title><source>Trends Microbiol.</source><volume>25</volume><year>2017</year><fpage>35</fpage><lpage>48</lpage><pub-id pub-id-type="pmid">27743750</pub-id></element-citation></ref><ref id="b0055"><mixed-citation publication-type="other" id="h0055">Gorbalenya, A.E., 2001. Big nidovirus genome, in: The Nidoviruses. Springer, pp. 1&#x02013;17.</mixed-citation></ref><ref id="b0060"><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>R.L.</given-names></name><name><surname>Donaldson</surname><given-names>E.F.</given-names></name><name><surname>Baric</surname><given-names>R.S.</given-names></name></person-group><article-title>A decade after SARS: strategies for controlling emerging coronaviruses</article-title><source>Nat. Rev. Microbiol.</source><volume>11</volume><year>2013</year><fpage>836</fpage><lpage>848</lpage><pub-id pub-id-type="pmid">24217413</pub-id></element-citation></ref><ref id="b0065"><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Halgren</surname><given-names>T.A.</given-names></name></person-group><article-title>Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94</article-title><source>J. Comput. Chem.</source><volume>17</volume><year>1996</year><fpage>490</fpage><lpage>519</lpage><pub-id pub-id-type="doi">10.1002/(SICI)1096-987X(199604)17:5/6&#x0003c;490::AID-JCC1&#x0003e;3.0.CO;2-P</pub-id></element-citation></ref><ref id="b0070"><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>H&#x000e9;zode</surname><given-names>C.</given-names></name></person-group><article-title>Treatment of hepatitis C: results in real life</article-title><source>Liver Int.</source><volume>38</volume><year>2018</year><fpage>21</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">29427481</pub-id></element-citation></ref><ref id="b0075"><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Jo</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>S.</given-names></name><name><surname>Shin</surname><given-names>D.H.</given-names></name><name><surname>Kim</surname><given-names>M.-S.</given-names></name></person-group><article-title>Inhibition of SARS-CoV 3CL protease by flavonoids</article-title><source>J. Enzyme Inhib. Med. Chem.</source><volume>35</volume><year>2020</year><fpage>145</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">31724441</pub-id></element-citation></ref><ref id="b0080"><mixed-citation publication-type="other" id="h0080">Khare, C.P., 2007. Vinca pusilla Murr., in: Khare, C.P. (Ed.), Indian Medicinal Plants: An Illustrated Dictionary. Springer New York, New York, NY, p. 1. https://doi.org/10.1007/978-0-387-70638-2_1743.</mixed-citation></ref><ref id="b0085"><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Lacroix</surname><given-names>A.</given-names></name><name><surname>Duong</surname><given-names>V.</given-names></name><name><surname>Hul</surname><given-names>V.</given-names></name><name><surname>San</surname><given-names>S.</given-names></name><name><surname>Davun</surname><given-names>H.</given-names></name><name><surname>Omaliss</surname><given-names>K.</given-names></name><name><surname>Chea</surname><given-names>S.</given-names></name><name><surname>Hassanin</surname><given-names>A.</given-names></name><name><surname>Theppangna</surname><given-names>W.</given-names></name><name><surname>Silithammavong</surname><given-names>S.</given-names></name></person-group><article-title>Genetic diversity of coronaviruses in bats in Lao PDR and Cambodia</article-title><source>Infect. Genet. Evol.</source><volume>48</volume><year>2017</year><fpage>10</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">27932284</pub-id></element-citation></ref><ref id="b0090"><mixed-citation publication-type="other" id="h0090">Lai, M.M.C., 2001. Coronaviridae: the viruses and their replication. In Fields Virology, Fourth Edition (Knipe DM, Howley PM, eds), Lippincott Williams and Wilkins, Philadelphia, pp. 1163&#x02013;1185.</mixed-citation></ref><ref id="b0095"><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Laskowski</surname><given-names>R.A.</given-names></name><name><surname>Swindells</surname><given-names>M.B.</given-names></name></person-group><article-title>LigPlot+: multiple ligand-protein interaction diagrams for drug discovery</article-title><source>J. Chem. Inf. Model.</source><volume>51</volume><year>2011</year><fpage>2778</fpage><lpage>2786</lpage><pub-id pub-id-type="doi">10.1021/ci200227u</pub-id><pub-id pub-id-type="pmid">21919503</pub-id></element-citation></ref><ref id="b0100"><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H.-J.</given-names></name><name><surname>Shieh</surname><given-names>C.-K.</given-names></name><name><surname>Gorbalenya</surname><given-names>A.E.</given-names></name><name><surname>Koonin</surname><given-names>E.V.</given-names></name><name><surname>La Monica</surname><given-names>N.</given-names></name><name><surname>Tuler</surname><given-names>J.</given-names></name><name><surname>Bagdzhadzhyan</surname><given-names>A.</given-names></name><name><surname>Lai</surname><given-names>M.M.C.</given-names></name></person-group><article-title>The complete sequence (22 kilobases) of murine coronavirus gene 1 encoding the putative proteases and RNA polymerase</article-title><source>Virology</source><volume>180</volume><year>1991</year><fpage>567</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">1846489</pub-id></element-citation></ref><ref id="b0105"><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Lipinski</surname><given-names>C.A.</given-names></name></person-group><article-title>Lead- and drug-like compounds: the rule-of-five revolution</article-title><source>Drug Discov. Today. Technol.</source><volume>1</volume><year>2004</year><fpage>337</fpage><lpage>341</lpage><pub-id pub-id-type="doi">10.1016/j.ddtec.2004.11.007</pub-id><pub-id pub-id-type="pmid">24981612</pub-id></element-citation></ref><ref id="b0110"><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>Coronavirus Pandemic&#x02014;Therapy and Vaccines</article-title><source>Biomedicines</source><volume>8</volume><year>2020</year><fpage>109</fpage></element-citation></ref><ref id="b0115"><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Mohanraj</surname><given-names>K.</given-names></name><name><surname>Karthikeyan</surname><given-names>B.S.</given-names></name><name><surname>Vivek-Ananth</surname><given-names>R.P.</given-names></name><name><surname>Chand</surname><given-names>R.P.B.</given-names></name><name><surname>Aparna</surname><given-names>S.R.</given-names></name><name><surname>Mangalapandi</surname><given-names>P.</given-names></name><name><surname>Samal</surname><given-names>A.</given-names></name></person-group><article-title>IMPPAT: A curated database of I ndian M edicinal P lants, P hytochemistry A nd T herapeutics</article-title><source>Sci. Rep.</source><volume>8</volume><year>2018</year><fpage>1</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">29311619</pub-id></element-citation></ref><ref id="b0120"><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>G.M.</given-names></name><name><surname>Huey</surname><given-names>R.</given-names></name><name><surname>Lindstrom</surname><given-names>W.</given-names></name><name><surname>Sanner</surname><given-names>M.F.</given-names></name><name><surname>Belew</surname><given-names>R.K.</given-names></name><name><surname>Goodsell</surname><given-names>D.S.</given-names></name><name><surname>Olson</surname><given-names>A.J.</given-names></name></person-group><article-title>AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility</article-title><source>J. Comput. Chem.</source><volume>30</volume><year>2009</year><fpage>2785</fpage><lpage>2791</lpage><pub-id pub-id-type="doi">10.1002/jcc.21256</pub-id><pub-id pub-id-type="pmid">19399780</pub-id></element-citation></ref><ref id="b0125"><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Needle</surname><given-names>D.</given-names></name><name><surname>Lountos</surname><given-names>G.T.</given-names></name><name><surname>Waugh</surname><given-names>D.S.</given-names></name></person-group><article-title>Structures of the Middle East respiratory syndrome coronavirus 3C-like protease reveal insights into substrate specificity</article-title><source>Acta Crystallogr. Sect. D Biol. Crystallogr.</source><volume>71</volume><year>2015</year><fpage>1102</fpage><lpage>1111</lpage><pub-id pub-id-type="pmid">25945576</pub-id></element-citation></ref><ref id="b0130"><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>O&#x02019;Boyle</surname><given-names>N.M.</given-names></name><name><surname>Banck</surname><given-names>M.</given-names></name><name><surname>James</surname><given-names>C.A.</given-names></name><name><surname>Morley</surname><given-names>C.</given-names></name><name><surname>Vandermeersch</surname><given-names>T.</given-names></name><name><surname>Hutchison</surname><given-names>G.R.</given-names></name></person-group><article-title>Open Babel: An open chemical toolbox</article-title><source>J. Cheminform.</source><volume>3</volume><year>2011</year><fpage>33</fpage><pub-id pub-id-type="doi">10.1186/1758-2946-3-33</pub-id><pub-id pub-id-type="pmid">21982300</pub-id></element-citation></ref><ref id="b0135"><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Padron-Regalado</surname><given-names>E.</given-names></name></person-group><article-title>Vaccines for SARS-CoV-2: lessons from other coronavirus strains</article-title><source>Infect. Dis. Ther.</source><volume>9</volume><year>2020</year><fpage>255</fpage><lpage>274</lpage></element-citation></ref><ref id="b0140"><element-citation publication-type="journal" id="h0140"><person-group person-group-type="author"><name><surname>Pathala</surname><given-names>D.</given-names></name><name><surname>Harini</surname><given-names>A.</given-names></name><name><surname>Hegde</surname><given-names>P.L.</given-names></name></person-group><article-title>A review on gambhari (Gmelina arborea Roxb.)</article-title><source>J. Pharmacogn. Phytochem.</source><volume>4</volume><year>2015</year><fpage>127</fpage><lpage>132</lpage></element-citation></ref><ref id="b0145"><element-citation publication-type="journal" id="h0145"><person-group person-group-type="author"><name><surname>Sander</surname><given-names>T.</given-names></name><name><surname>Freyss</surname><given-names>J.</given-names></name><name><surname>von Korff</surname><given-names>M.</given-names></name><name><surname>Rufener</surname><given-names>C.</given-names></name></person-group><article-title>DataWarrior: an open-source program for chemistry aware data visualization and analysis</article-title><source>J. Chem. Inf. Model.</source><volume>55</volume><year>2015</year><fpage>460</fpage><lpage>473</lpage><pub-id pub-id-type="doi">10.1021/ci500588j</pub-id><pub-id pub-id-type="pmid">25558886</pub-id></element-citation></ref><ref id="b0150"><element-citation publication-type="journal" id="h0150"><person-group person-group-type="author"><name><surname>Simas</surname><given-names>P.V.M.</given-names></name><name><surname>de Souza Barnab&#x000e9;</surname><given-names>A.C.</given-names></name><name><surname>Dur&#x000e3;es-Carvalho</surname><given-names>R.</given-names></name><name><surname>de Lima Neto</surname><given-names>D.F.</given-names></name><name><surname>Caserta</surname><given-names>L.C.</given-names></name><name><surname>Artacho</surname><given-names>L.</given-names></name><name><surname>Jacomassa</surname><given-names>F.A.F.</given-names></name><name><surname>Martini</surname><given-names>M.C.</given-names></name><name><surname>dos Santos</surname><given-names>M.M.A.B.</given-names></name><name><surname>Felippe</surname><given-names>P.A.N.</given-names></name></person-group><article-title>Bat coronavirus in Brazil related to appalachian ridge and Porcine epidemic diarrhea viruses</article-title><source>Emerg. Infect. Dis.</source><volume>21</volume><year>2015</year><fpage>729</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">25811911</pub-id></element-citation></ref><ref id="b0155"><element-citation publication-type="journal" id="h0155"><person-group person-group-type="author"><name><surname>Su</surname><given-names>S.</given-names></name><name><surname>Wong</surname><given-names>G.</given-names></name><name><surname>Shi</surname><given-names>W.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Lai</surname><given-names>A.C.K.</given-names></name><name><surname>Zhou</surname><given-names>J.</given-names></name><name><surname>Liu</surname><given-names>W.</given-names></name><name><surname>Bi</surname><given-names>Y.</given-names></name><name><surname>Gao</surname><given-names>G.F.</given-names></name></person-group><article-title>Epidemiology, genetic recombination, and pathogenesis of coronaviruses</article-title><source>Trends Microbiol.</source><volume>24</volume><year>2016</year><fpage>490</fpage><lpage>502</lpage><pub-id pub-id-type="pmid">27012512</pub-id></element-citation></ref><ref id="b0160"><element-citation publication-type="journal" id="h0160"><person-group person-group-type="author"><name><surname>Trott</surname><given-names>O.</given-names></name><name><surname>Olson</surname><given-names>A.J.</given-names></name></person-group><article-title>AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading</article-title><source>J. Comput. Chem.</source><volume>31</volume><year>2010</year><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1002/jcc.21334</pub-id><pub-id pub-id-type="pmid">19499576</pub-id></element-citation></ref><ref id="b0165"><element-citation publication-type="journal" id="h0165"><person-group person-group-type="author"><name><surname>Veber</surname><given-names>D.F.</given-names></name><name><surname>Johnson</surname><given-names>S.R.</given-names></name><name><surname>Cheng</surname><given-names>H.-Y.</given-names></name><name><surname>Smith</surname><given-names>B.R.</given-names></name><name><surname>Ward</surname><given-names>K.W.</given-names></name><name><surname>Kopple</surname><given-names>K.D.</given-names></name></person-group><article-title>Molecular properties that influence the oral bioavailability of drug candidates</article-title><source>J. Med. Chem.</source><volume>45</volume><year>2002</year><fpage>2615</fpage><lpage>2623</lpage><pub-id pub-id-type="pmid">12036371</pub-id></element-citation></ref><ref id="b0170"><element-citation publication-type="journal" id="h0170"><person-group person-group-type="author"><name><surname>Weiss</surname><given-names>S.R.</given-names></name><name><surname>Navas-Martin</surname><given-names>S.</given-names></name></person-group><article-title>Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus</article-title><source>Microbiol. Mol. Biol. Rev.</source><volume>69</volume><year>2005</year><fpage>635</fpage><lpage>664</lpage><pub-id pub-id-type="pmid">16339739</pub-id></element-citation></ref><ref id="b0175"><element-citation publication-type="journal" id="h0175"><person-group person-group-type="author"><name><surname>Wishart</surname><given-names>D.S.</given-names></name><name><surname>Knox</surname><given-names>C.</given-names></name><name><surname>Guo</surname><given-names>A.C.</given-names></name><name><surname>Cheng</surname><given-names>D.</given-names></name><name><surname>Shrivastava</surname><given-names>S.</given-names></name><name><surname>Tzur</surname><given-names>D.</given-names></name><name><surname>Gautam</surname><given-names>B.</given-names></name><name><surname>Hassanali</surname><given-names>M.</given-names></name></person-group><article-title>DrugBank: a knowledgebase for drugs, drug actions and drug targets</article-title><source>Nucleic Acids Res.</source><volume>36</volume><year>2008</year><fpage>D901</fpage><lpage>D906</lpage><pub-id pub-id-type="pmid">18048412</pub-id></element-citation></ref><ref id="b0180"><element-citation publication-type="journal" id="h0180"><person-group person-group-type="author"><name><surname>Woo</surname><given-names>P.C.Y.</given-names></name><name><surname>Lau</surname><given-names>S.K.P.</given-names></name><name><surname>Lam</surname><given-names>C.S.F.</given-names></name><name><surname>Lau</surname><given-names>C.C.Y.</given-names></name><name><surname>Tsang</surname><given-names>A.K.L.</given-names></name><name><surname>Lau</surname><given-names>J.H.N.</given-names></name><name><surname>Bai</surname><given-names>R.</given-names></name><name><surname>Teng</surname><given-names>J.L.L.</given-names></name><name><surname>Tsang</surname><given-names>C.C.C.</given-names></name><name><surname>Wang</surname><given-names>M.</given-names></name></person-group><article-title>Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavi</article-title><source>J. Virol.</source><volume>86</volume><year>2012</year><fpage>3995</fpage><lpage>4008</lpage><pub-id pub-id-type="pmid">22278237</pub-id></element-citation></ref><ref id="b0185"><element-citation publication-type="journal" id="h0185"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>F.</given-names></name><name><surname>Zhao</surname><given-names>S.</given-names></name><name><surname>Yu</surname><given-names>B.</given-names></name><name><surname>Chen</surname><given-names>Y.-M.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name><name><surname>Song</surname><given-names>Z.-G.</given-names></name><name><surname>Hu</surname><given-names>Y.</given-names></name><name><surname>Tao</surname><given-names>Z.-W.</given-names></name><name><surname>Tian</surname><given-names>J.-H.</given-names></name><name><surname>Pei</surname><given-names>Y.-Y.</given-names></name></person-group><article-title>A new coronavirus associated with human respiratory disease in China</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">32015508</pub-id></element-citation></ref><ref id="b0190"><element-citation publication-type="journal" id="h0190"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P.</given-names></name><name><surname>Yang</surname><given-names>X.-L.</given-names></name><name><surname>Wang</surname><given-names>X.-G.</given-names></name><name><surname>Hu</surname><given-names>B.</given-names></name><name><surname>Zhang</surname><given-names>L.</given-names></name><name><surname>Zhang</surname><given-names>W.</given-names></name><name><surname>Si</surname><given-names>H.-R.</given-names></name><name><surname>Zhu</surname><given-names>Y.</given-names></name><name><surname>Li</surname><given-names>B.</given-names></name><name><surname>Huang</surname><given-names>C.-L.</given-names></name></person-group><article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title><source>Nature</source><volume>579</volume><year>2020</year><fpage>270</fpage><lpage>273</lpage><pub-id pub-id-type="pmid">32015507</pub-id></element-citation></ref><ref id="b0195"><mixed-citation publication-type="other" id="h0195">Ziebuhr, J., 2005. The coronavirus replicase, in: Coronavirus Replication and Reverse Genetics. Springer, pp. 57&#x02013;94.</mixed-citation></ref><ref id="b0200"><element-citation publication-type="journal" id="h0200"><person-group person-group-type="author"><name><surname>Ziebuhr</surname><given-names>J.</given-names></name><name><surname>Thiel</surname><given-names>V.</given-names></name><name><surname>Gorbalenya</surname><given-names>A.E.</given-names></name></person-group><article-title>The autocatalytic release of a putative RNA virus transcription factor from its polyprotein precursor involves two paralogous papain-like proteases that cleave the same peptide bond</article-title><source>J. Biol. Chem.</source><volume>276</volume><year>2001</year><fpage>33220</fpage><lpage>33232</lpage><pub-id pub-id-type="pmid">11431476</pub-id></element-citation></ref></ref-list><ack id="ak005"><title>Acknowledgements</title><p>The authors would like to extend their sincere appreciation to the Researchers Supporting Project number (RSP-2019/154), King Saud University, Riyadh, Saudi Arabia. J. Lee thanks to <funding-source id="gp015"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002462</institution-id><institution>Chungnam National University</institution></institution-wrap></funding-source>, Daejeon, Republic of Korea for the funding support. The authors thank the <funding-source id="gp005"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100011665</institution-id><institution>Deanship of Scientific Research</institution></institution-wrap></funding-source> and RSSU at <funding-source id="gp020"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100002383</institution-id><institution>King Saud University</institution></institution-wrap></funding-source> for their technical support.</p></ack><fn-group><fn id="d33e2317"><p id="np005">Peer review under responsibility of King Saud University.</p></fn></fn-group></back></article>